Pharmacokinetic and Pharmacodynamic Assessment of a Novel, Pharmaceutical Lipid-Aspirin Complex

NCT04008979 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2019-07-05

No results posted yet for this study

Summary

Prospective, Randomized, Crossover, Bioequivalence study

Conditions

  • Bioequivalence

Interventions

DRUG

Aspirin

Aspirin - lipid complex

Sponsors & Collaborators

  • PLx Pharma

    lead INDUSTRY

Principal Investigators

  • Upendra Marathi, PhD · PLx Pharma

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-02-11
Primary Completion
2008-06-10
Completion
2008-06-10
FDA Drug
Yes

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04008979 on ClinicalTrials.gov